Codexis (CDXS) Q2 2026 Earnings Call Transcript
Codexis (CDXS) reported Q2 2026 revenue of $14.9M, down from $15.3M in Q2 2025. Product revenue rose to $13.2M, while R&D revenue fell to $1.7M. Net loss narrowed to $12.0M. The company guided full-year revenue to $72M-$76M and maintained a high 60% gross margin target. It plans to invest $25M in a GMP facility and expects a 30-fold increase in siRNA market demand by 2035. CDXS has 14 commercial products and 15 clinical programs in Phase II/III. Management highlighted progress in ECOsynthesis pl
How this was made
The 30-second read
Why it matters
The call updates traders on near-term financial trajectory (Q2 results, full-year revenue and gross margin guidance) and on execution drivers (GMP capex, start and ramp timing, FDA engagement, CDMO technology transfer).
Market read
For CDXS, the tradable elements are the updated 2026 revenue and gross margin ranges, the stated cash runway, and the concrete GMP and regulatory timeline that frames 2H26 expectations.
What to watch
Customer ordering patterns are explicitly described as lumpy and unpredictable, and the article does not quantify how much of the guided revenue depends on the CDMO partner long-term contract negotiations.
Background
Codexis is transitioning from small-molecule biocatalysis toward large-scale siRNA manufacturing using its ECOsynthesis platform, with a dedicated GMP facility planned.
Ticker impact
Codexis reported Q2 2026 revenue of $14.9M, guided full-year revenue to $72M-$76M, and outlined a $25M GMP facility build-out.
Likely supports a modest positive bias if investors view the GMP ramp and margin trajectory as credible, but execution risk remains high given lumpy ordering and facility timing.
The article provides concrete financials (revenue, net loss, gross margin) plus forward guidance (revenue range, high-60% gross margin) and specific operational milestones (GMP start 2H26, full capability end-2027, FDA meeting Q4 2026).
Market effects
Highlights a potential capacity bottleneck narrative for siRNA manufacturing and increased focus on enzymatic (ECOsynthesis) scale-up.
No specific regional market impact disclosed.
Could influence global CDMO and siRNA therapeutic manufacturing capacity expectations if GMP ramp proceeds as planned.
Counterpoint
The revenue and margin improvement may be more product-mix driven than demand durability, and the GMP ramp could slip, making 2H26 concentration a risk rather than a catalyst.
Key entities
- companyCodexis
Reported Q2 2026 results and provided full-year 2026 guidance plus operational milestones for ECOsynthesis and siRNA manufacturing.
- executiveAlison Moore
CEO who emphasized the increasing clarity of ECOsynthesis impact and discussed forward-looking execution.
- executiveGeorgia L. Erbez
CFO/CBO who delivered financial results, guidance, and noted lumpy and unpredictable ordering patterns.
- executiveStefan Lutz
CSO who discussed engineered enzymes, stereochemical control, and introduced Starterless ECOsynthesis.
- executiveBritton Jimenez
SVP Sales and Marketing who discussed CDMO customer motivation and technology transfer into partner facilities.
